Curriculum Vitae Stefan Endres, Prof., M.D., B.A. (Harvard) Phone: 0049-89-44005-7300 Mobile: 0049-152-0155 9736, E-mail: endres@lmu.de Born: June 17, 1957 in Augsburg, Germany Married; one daughter of 25 years, one son of 21 years Past and Present Leading Positions 2017 - Benennung in den Beirat der BioM Biotech Cluster Development Gesellschaft

durch Staatsministerin Isle Aigner, Bayerisches Wirtschaftsministerium 2018 - Berufung als Mitglied des Wissenschaftlichen Beirats der Bundesärztekammer

(Amtsperiode 2018 bis 2021) 2016 - German Cancer Consortium (DKTK); Member of local steering committee;

Partner site Munich 2015 - Speaker of newly established Marie-Sklodowska-Curie training network

“Immutrain: Immunotherapy of Cancer”, funded by Horizon 2020 (2015 to 2018) 2014 - Speaker of newly established International Doctoral Program “i-Target:

Immuntargeting of Cancer”, funded by Elite Network of Bavaria (2014 to 2018) 2013 - Scientific advisor for the Paul Martini-Stiftung 2013 - Member of the Scientific Board (Wissenschaftskommission) of the Else Kröner

Fresenius-Stiftung; since 2015 Deputy Chairman 2012 - Area coordinator (Area D Protein nucleic acid interactions) and PI, excellence

cluster Center of Integrated Protein Science (CIPS-M), 2012 to 2017 2012 Member of search committee for chief of medicine (Ärztlicher Direktor) of

Ludwig-Maximilian University Clinics 2011 - Member of Scientific Advisory Committee, Vaccine and Immunotherapy Center

(VIC), Massachusetts General Hospital, Harvard University, Boston 2011 - Board of Directors (Aufsichtsrat), reelected for term 2011 to 2016 2011 Appointment as Visiting Professor Harvard Medical School, Division of

Immunology (Laboratory Prof. von Andrian), April to August 2011 2011 Appointment as Jury Member for European Research Council (ERC),

Selection Jury Advanced Investigator Grant, Panel Immunology and Infection 2009 - 2015 Spokesman of the DFG Graduate Research Centre GK 1202 “Oligonucleoti-

des in cell biology and therapy” (renewal with 3,535,078 Euro funding until 2015) 2007 - Dean of Research, Medical Faculty, Ludwig-Maximilian University; reelection

for terms 2010 to 2013 and 2013 to 2016 (2013 budget for research and education: 148 million Euro); excellence university in the German excellence initiative

2007 - Chairman of the newly formed Research Committee of the Medical Faculty 2007 - Principal investigator in the excellence cluster Center of Integrated Protein

Science Munich (CIPS-M) 2007 - 2012 LMUexcellent Research Professor as one out of eleven grantees 2007 - 2012 Member of the Board of the Clinical Study Center, newly established to

coordinate clinical studies at the Ludwig-Maximilian University 2006 - Board of Directors (Aufsichtsrat) of Ludwig-Maximilian University Clinics for

five more years (2009 annual budget: 845 million Euro; 9,929 employees) 2006 - Consultant for biotech companies designing phase II studies for immunotherapy

of patients with autoimmune or infectious diseases 2005 - 2006 Member of the Board (Vorstand) of Ludwig-Maximilian University Clinics

Endres, CV 2 2003 - Member of the Ethics Committee (Bayerische Landesärztekammer) 2003 - 2007 Principal Investigator of investigator-intitated phase II study with autologous

dendritic cell vaccination for patients with pancreatic cancer 2002 - Member of the Faculty Council (Fachbereichsrat), Medical Faculty, LMU 1998 - 2009 Chairman, Subcommittee on Drugs in Gastrointestinal Disease 1997 - 2004 Course Director teaching program of Harvard Educational Alliance 1997 - Member of Committee on Drug Evaluation (Arzneimittelkommission) 1997 - Full Professor of Clinical Pharmacology, Director, Division of Clinical

Pharmacology, Ludwig-Maximilian University Professional Training 2003 Board-certified Immunologist (German Society of Immunology) 1996 Subspeciality boards Gastroenterology, senior physician at intensive care unit 1993 Subspeciality boards Intensive Care Medicine, Attending Physician at the

Department of Internal Medicine 1992 Habilitation for Internal Medicine (Assistant Professor) 1991 Specialty boards Internal Medicine 1988 -1997 Residency, Subspecialty Fellowship and Research Group Leader at

Medizinische Klinik Innenstadt, Ludwig-Maximilians- Universität 1987 - 1988 Research Fellow at the Department of Infectious Diseases, New England Medical

Center, Boston (group of Prof. Charles Dinarello); immunology research 1984 -1987 Medical Internship at Medizinische Klinik Innenstadt, Ludwig-Maximilians-

Universität München (Director: Prof. Dr. P. C. Scriba) Education 1984 M.D. degree with magna cum laude, Ludwig-Maximilians- Universität, Munich,

Germany 1983 State Medical Boards, Munich 1982 Core clinical clerkship Internal Medicine at Beth Israel Hospital, Harvard

Medical School, Boston 1979 Bachelor of Arts degree with magna cum laude, Department of Biochemistry

and Immunology, Harvard University 1977 - 1979 Two years study at Harvard University, Cambridge, Massachusetts 1975 Entering Medical School at Ludwig-Maximilians- Universität, Munich 1974 Second Prize in German Federal Mathematics Competition (Bundeswettwerb

Mathematik) 1967 - 1975 Secondary School Gymnasium bei St. Anna (humanistic, modern languages),

Augsburg; skipping grade 10. Publications Total of 185 original research papers in peer-reviewed journals, 43 review articles, and 28 books or book chapters. The cumulative journal impact factor is 1097,8. The number of total citations over 19.583 (June 2015) and the h-index (Hirsch) is 63. For a complete list of publications, see www.klinische-pharmakologie.de ® Publikationen. 55 invited lectures, organisation of 21 scientific conferences and seven patents or patent applications. 2012 153. Dann A, Poeck H, Croxford A, Gaupp S, Kierdorf K, Knust M, Pfeifer D, Maihoefer C, Endres S, Kalinke U, Meuth S, Wiendl H, Knobeloch KP, Akira S, Waisman A, Hartmann G, Prinz M.

Endres, CV 3 Cytosolic RIG-like-helicases act as negative regulators of sterile inflammation in the CNS. Nature Neuroscience 2012; 15:98-106. (JIF 15,3) 154. Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, Kremer M, Sutter G, Endres S, Schmidt A, Rothenfusser S. Cytosolic DNA triggers mitochondrial apoptosis via DNA-damage signalling proteins independently of AIM2 and RNA polymerase III. Journal of Immunology 2012; 188:394-403. (JIF 5,5) 155. Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD Models: influence of genetic and environmental factors. Digestive Diseases 2012; 1:82-90. (JIF 2,7) 2013 156. Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clincial score and TNF expression in experimental colitis in mice. PLoS One 2013; 8:56867. (JIF 4,1) 157. Ellermeier J, Wei J,Düwell P, Hoves S, Stieg M, Adunka T, Nörenberg D, Anders HJ, Mayr D, Pöck H, Hartmann G, Endres S, Schnurr M. Targeting pancreatic cancer with bifunctional 5`triphosphate-si-RNA combining TGF-β1 silencing with RIG-I activation. Cancer Research 2013; 73:1709-20. (JIF 7,9) 158. Heidegger S, Kirchner SK, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, Endres S, Bourquin C. TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice. Journal of Immunology 2013; 190:5313-20. (JIF 5,8) 159. Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R. The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Molecular Medicine 2013; 5:919-34. (JIF 10,3) 160. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Merk M, Rothenfußer S, Schnurr M, Huber RM, Sauter G, Wilczak W, Endres S. Interleukin-22 is frequently in lung cancer and may contribute to tumor progression in chemotherapy-resistant disease. Journal of Thoracic Oncology 2013; 8:1032-1042. (JIF 3,7) 161. Heidegger S*, Anz D*, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenaecher K, Radtke-Schuller S, Endres S, Bourquin C. Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice. Blood 2013; 122:2591-9. (JIF 9,1) *diese Autoren leisteten gleichwertigen Beitrag 2014 162. Kobold S, Merk M, Hofer L, Peters P, Bucala R, Endres S. The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model. Oncotarget 2014; 5:103-7. (JIF 6,6)

Endres, CV 4 163. Anz D, Kruger S, Haubner S, Rapp M, Bourquin C, Endres S. The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, Obestity and Metabolism 2014; 16:569-72. JIF (5,2) 164. Kim S, Kaiser V, Beier E, Bechheim M, Guenthner-Biller M, Ablasser A, Berger M, Endres S, Hartmann G, Hornung V. Self-priming determines high type I IFN production by plasmacytoid dendritic cells. European Journal of Immunology 2014; 44:807-18. (JIF 5,0) 165. Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in an murine pancreatic carcinoma model. Cancer Immunology Immuntherapy 2014; 63:321-33. (JIF 3,6) 166. Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, Endres S, Schnurr M. RIG-I-like helicases induce immunogenic cell detah of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death and Differentiation 2014; 21:160. (JIF 8,4) 167. Kobold S,Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S. Selective bispezific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. The Journal of the National Cancer Institute 2014; 107:364. (JIF 15,2) 2015 168. Hoffmann F, Schmidt A, Dittmann C, Wisskirchen C, Hellmuth J, Willms S, Gilmore R, Glas J, Folwaczny M, Müller T, Berg T, Spengler U, Fitzmaurice K, Reisch M, Rice C, Endres S, Rothenfusser S. Polymorphisms in MDA-5 link protein function to clearance of hepatitis C virus. Hepatology 2015; 61:460-70. (JIF 10,4) 169. Bauer C, Hees C, Sterzik A, Bauernfeind F, Mak´Anyengo R, Duewell P, Lehr HA, Noessner E, Wank R, Trauzold A, Endres S, Dauer M, Schnurr M. Pro- and anti-apoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells towards gemcitabine and T cell-mediated cytotoxicity. Journal of Immunotherapy 2015; 38:116-26. (JIF 3,4) 170. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. OncoImmunology 2015; 4:e1029698. (JIF 6,3) 171. Freier C, Kuhn C, Rapp M, Endres S, Mayr D, Friese K, Anz D, Jeschke U. Expression of CCL22 and infiltration by regulatory T-cells are increased in the decidua of human miscarriage placentas. American Journal of Reproductive Immunology 2015; 74:216-27. (JIF 2,7)

Endres, CV 5 172. Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger J, Schnurr M, Endres S #, Rothenfußer S#. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. The Journal of the National Cancer Institute 2015; 107. (JIF 15,2) * contributed equally to this study # share senior authorship 173. Hotz C, Roetzer L, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C. TLR and RLR signaling is reprogrammed in opposite directions after detection of viral infection. The Journal of Immunology 2015; in press. (JIF 5,4) 174. Anz D , Rapp M, Eiber S, Koelzer V, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann G, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C. Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Research 2015; 61:460-70. (JIF 9,3) 175. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S. C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology 2015; 10:e0142523. (JIF 6,3) 176. Heidegger S, Alexander J, Endres S, Bourquin C, Hotz C. Mycoplasma hyorhinis-contaminated cell lines activate primary innate immune cells via a protease-sensitive factor. PLOS ONE 2015; 10:e0142523.. (JIF 3,7) 2016 177. Heidegger S, Gößl D, Schmidt A, Niedermayer S, Argyo Ch, Endres S, Bein T, Bourquin C. Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery. Nanaoscale 2016; 8:938-48. (JIF 7,4) 178. Wiedemann G, Knott M, Rapp M, Haubner S, Fesseler J, Layritz P, Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D. Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology 2016; in press. (JIF 7,4) 179. Wiedemann G, Jacobi S, Chaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S. A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncoimmunology 2016; 5:e1189051. (JIF 6,3) 180. Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S. Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases. BMC Cancer Journal 2016; 16:409. (JIF 3,8) 181. Freier CP, Kuhn C, Endres S, Mayr D, Freise K, Jeschke U, Anz D. FOXP3+ cells recruited by CCL22 into breast cancer correlates with less tumor nodal infiltration. BMC Cancer 2016; 16:409. (JIF 1,9)

Endres, CV 6 2017 182. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S. Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences USA 2017, 14:12994-12999; (JIF 9,6; Zitierungen n = 46) * contributed equally to this study 2018 183. Makanyengo R, Duewell P, Reichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer Ch. Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut. JCI Insight 2018; in press. 184. Metzger P, Kirchleitner S, König L, Hörth Ch, Kobold S, Endres S, Schnurr M, Duewell P. Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Science Reports 2018; 8:8810. (JIF 4,8) 185. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S. PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma. Frontiers in Immunology 2018; 9:1955. (JIF 6,4) 186. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Düwell P, Endres S, Klein Ch, Kobold S. High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. British Journal of Cancer 2018; 120:79-87. (JIF 6,2) 187. Wiedemann G, Aithal C, Kraechan A, Heise C, Cadilha B, Zhang J, Duewell P, Robert Ballotti, Endres S, Bertolotto C, Kobold S. Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma. Translational Oncology 2018; 12:350-360. (JIF 3,1) 188. Kuehnemuth B, Piseddu I, Wiedemann G, Lauseker M, Kuhn Ch, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D. CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer 2018; 18:1278. (JIF 3,3) Third-part funds since 2007

Endres, CV 7

Projekt Förderer Personal- stellen*

Zusätzliche Verbrauchs-mittel

Fördermittel gesamt (Euro)

1. Forschungs-professur im Rahmen der 3. Förderlinie der Exzellenzinitiative des Bundes und der Länder

Principal Investigator: S. Endres 2007 bis 2012

1,5 BAT IIa für 4 Jahre

505.917.- 905.917.-

2. Fortsetzungsantrag Graduiertenkolleg „Oligonukleotide in Zellbiologie und Therapie“

Graduiertenkolleg der Deutschen Forschungsge- meinschaft; GRK 1202/1; Sprecher S. Endres 2010 bis 2014

21 Dok-toranden-stipendien1 BAT IIa für 4,5 Jahre

(3.535.078.-) davon Projekte Bourquin, Endres und Anz, Endres, (2 von 11) plus zentrale Mittel = 900.000.-

3. Cluster of Integrated Protein Science (CIPS-M); 2. Förderlinie der Exzellenzinitiative des Bundes und der Länder

Principal Investigator: S. Endres 2012 bis 2017

100.000.- für 5 Jahre

500.000.-

4. Fortsetzungsantrag A translational approach to immunostimulatory RNA oligonucleotides

Bayerisches Immuntherapie-Netzwerk (BayImmuNet); Principal investigators: S. Endres, S. Kobold 2011 bis 2013

101.100.- (aus Ministerium: 70.770.-, aus Dekanatsmitteln: 30.330.-)

5. Imaging and Therapeutic Targeting of Lymphangiogenesis in Melanoma

Melanoma Research Association, Washingtion, DC, USA Principal investigators: S. Endres, S. Kobold 2013 bis 2015

100.000.-

6. Kooperationsvertrag präklinische TLR-7/8 Agonisten

4SC, Spitzencluster m4 2013 bis 2015

1 TVL-13 für 2 Jahre 160.000.-

40.000.- 200.000.-

7. i-Target: Immunotherapy of Cancer

Internationales Doktorandenkolleg des Elitenetzwerks Bayern, Sprecher: S. Endres, 2014 bis 2018

12 Dok-toranden-stipendien (TVL 75 %) für 4 Jahre

(2.726.250.-) davon Projekte Endres und Kobold 523.680.- plus Koordinier-ungsmittel 136.428.-

8. Marie-Curie-Sklodowska-Network

Innovative Training Network "Immutrain", Sprecher: S. Endres, 2016 bis 2019

14 Dok-toranden-stellen

(3.627.525.-) davon Projekt Kobold-Endres 750.000.- plus Koordinier-ungsmittel 604.000.-

9. BMBF Projektträger Jülich: Onkattract

Principal investigators: S. Kobold, S. Endres 2017 bis 2020

2 Stellen auf TVL, E12-15; 2 Stellen auf TVL E1-11

1.202.588.-

Gesamtförderung Prof. Dr. Endres 2007 bis 2017

6.189.855.- Euro

Endres, CV 8

Prof. Dr. Stefan Endres Munich, January 16th 2019